Myeloma Paper of the Day, November 18th, Suggested by Robert Orlowski

Myeloma Paper of the Day, November 18th, Suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:

“Myeloma Paper of the Day:

Phase 1 first-in-human trial of natural ligand-based CAR T targeting BCMA & TACI (TriPRIL) in RRMM shows 80% ORR & 53% CR (56% among those w/ prior BCMA CAR) w/ 87% CRS rate (all grade 1) & 1 event each of ICANS & IEC-HS.”

Title: Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial

Authors: David F. Moreno, Ferran Nadeu, Marta Casado-Peláez, Caterina Mata, Ian Márquez-López, Marco A. Fernández, Sergi Vaqué, Elena Medina, Helena Llobregat, Marta Garrote, Joan Mañé, Oriol Cardús, Luis Gerardo Rodríguez-Lobato, Anna de Daniel, María Teresa Cibeira, Theo Gremen Oliveira, Elizaveta Kulaeva, Ester Lozano, Dolors Colomer, Laura Rosiñol, Ruben van Boxtel, Manel Esteller, Carlos Fernández de Larrea

You can read the full article on The Lancet Journal.

Myeloma Paper of the Day, November 18th, Suggested by Robert Orlowski

You can find other articles featuring Robert Orlowski on OncoDaily.